期刊文献+

三维适形放疗不同剂量分割治疗晚期非小细胞肺癌疗效观察

Observation of the effect of three-dimensional conformal radiation dose fractionation treatment of advanced non-small cell lung cancer
原文传递
导出
摘要 目的探讨三维适形放射不同剂量分割治疗晚期非小细胞肺癌(NSCLC)的近期疗效。方法148例NSCLC随机采用三维适形放疗(3DCRT)(观察组,75例)和常规分割照射治疗(对照组,73例),观察近期疗效和不良反应,随访患者治疗后1、2、3年生存情况。结果对照组总有效47例(64.4%),观察组总有效60例(80.0%),两组差异有统计学意义(x2=4.50,P〈0.05)。对照组1、2、3年生存率为50.7%、24.7%、8.2%,中位生存期为13个月;观察组分别为73.3%、45.3%、20.0%,中位生存期为19个月。两组生存率差异有统计学意义(x2=8.07、6.94、4.22,均P〈0.05)。观察组血液系统副反应发生率明显低于对照组(x2=4.73,P〈0.05),两组急性放射性肺炎、放射性食管炎发生率差异无统计学意义(p〉0.05)。结论3DCRT对晚期NSCLC近期疗效好,且治疗不良反应低,值得在临床上推广应用。 Objective To explore the effect of three-dimensional conformal radiation dose fractionation treat- ment of advanced non-smal! cell lung cancer(NSCLC). Methods 75 NSCLC patients were treated with hypofraction- ated 3DCRT( observation group ), while 73 cases were treated with conventional fractionated radiotherapy (control group). The efficacy and adverse reactions were observed ; Survival after treatment were followed up in 1,2,3 years. Lung function was detected before and after radiotherapy treatment, including FVC, FEV1 and CLCO. Results The total effective cases of control group were 47 cases patients (64.4%) , observation group's was 60 cases (80.0%), to- tal effective rate had statistically significant difference( X2 = 4. 50 ,P 〈 0. 05 ). Survival of control group aiter treatment in 1,2,3year were 50.7% ,24.7% , 8.2% , the median survival was 13 months, observation group's were 73.3% , 45.3 % , 20.0% , and 19 months. The survival of these two groups was statistically different ( X2 = 8.07,6.94,4.22, all P 〈 0.05 ). The patients blood system side effects of observation group were significantly lower than the control group (X2 = 4. 73, P 〈 0.05 ) ;acute radiation pneumonia, esophagitis of these two groups had no significant difference in the incidence( P 〉 0.05 ). Conclusion Hypofractionated 3DCRT treatment of advanced NSCLC had good e.ffect, and its adverse reactions was low, and it was worthy of clinical application.
出处 《中国基层医药》 CAS 2012年第13期1933-1934,共2页 Chinese Journal of Primary Medicine and Pharmacy
关键词 非小细胞肺 放射疗法 适形 Carcinoma,non-small-cell lung Radiotherapy,conformal
  • 相关文献

参考文献7

二级参考文献63

  • 1程中伟,张力.老年人晚期非小细胞肺癌化疗新进展[J].中国医学科学院学报,2004,26(3):330-334. 被引量:19
  • 2肖泽芬,章众,张红志,戴建荣,梁军,韩伟.用三维治疗计划系统评估食管癌常规放射治疗中肿瘤剂量的分布[J].中华放射肿瘤学杂志,2004,13(4):273-277. 被引量:174
  • 3Velu TJ.Structure,function and transforming potential of the epidermal growth factor receptor.Mol Cell Endocrinol,1990,70(3):205-216.
  • 4Denny W A.The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrusine kinases.Farmaco,2001,56(1-2):515-516.
  • 5Wakeling AE,Guy SP,Woodburu JR,et al.ZD1839(Iressa):an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.Cancer Res,2002,62(20):5749-5754.
  • 6Cohen MH,Williams GA,Sridhara R,et al.FDA drug approval summary:gefitinib(ZD1839)(Irmssa)tablets.Oncologist,2003,8(4):303-306.
  • 7Hainsworth JD,Mainwaring MG,Thomas M,et al.Gefitinib in the treatment of advanced.refractory non-small-cell lung cancer:re-sults in 124 patients.Clin Lung Cancer,2003,4(6):347-355.
  • 8LoRusso PM,Herbst RS,Rischin D,et al.Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD 1839 in nou-small cell lung cancer and other solid tumors.Clin Cancer Res,2003,9(6):2040-2048.
  • 9Ciardiello F,Caputo R,Bianco R,et al.Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839(Iressa),a selective epidermal growth factor receptor tyrosine kinase inhibitor.Clin Cancer Res,2001,7(5):1459-1465.
  • 10Gee JM,Nicholson RI.Expanding the therapeutic repertoire of epidermal growth factor recptor blockade:radiosensitization.Breast Cancer Res,2003,5(3):126-129.

共引文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部